Expression of Tetranectin in the Cerebrospinal Fluid of Patients with Parkinson Disease Pre- and Post-Dbs

Er-song WANG,Jin HU,Xiong-hui KUANG,Cai-hua XI,Hai-jun YAO,Jie HU,Jian-wen HU,Cheng-chuan JIANG
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2011.19.008
2011-01-01
Abstract:Objective To know whether or not tetranectin in cerebrospinal fluid (CSF) might serve as a potential biomarker in assessing and following therapeutic efficacy of deep brain stimulation (DBS) in Parkinson disease (PD) patients.Methods Two-dimensional difference gel electrophoresis (DIGE) technique,in combination with matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS),was used to determine the differentially expressed tetranectin and apolipoprotein A-Ⅰ (apo A-Ⅰ) during the perioperative period in the CSF of PD patients who underwent bilateral subthalamic nucleus (STN) DBS procedures.Western blotting was used to validate the data of proteomic analysis from the perioperative period,and also to determine the exact changes of these proteins in follow-up period.Results DIGE and Western blotting analysis both showed that the expression levels of tetranectin and apo A-Ⅰ were not significantly changed in perioperative period.In follow-up period,the expression level of apo A-Ⅰ remained stable whereas tetranectin was significantly increased,and interestingly,while the DBS was ceased in one patient because of suicide attempt,the level of tetranectin was significantly decreased.These changes of tetranectin paralleled the observed clinical effects of DBS.Conclusions Our preliminary results suggest that the variation of the expression level of tetranectin is related to the STN DBS,and tetranectin in CSF might thereby serve as a potential biomarker for DBS.
What problem does this paper attempt to address?